47 completed. 47 Phase 2, 4 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 47 | Completed 47 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 3 | Completed 3 |
Follow Liposarcoma: new trials by email Literature Review of Liposarcoma trials Research Report on Liposarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma Brigimadlin, Doxorubicin - Liposarcoma, Dedifferentiated | Phase 2 / Phase 3 | Completed | Boehringer Ingelheim | 400 | 2022-03-31 | 2026-03-02 |
| Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. Trabectedin, Pioglitazone Oral Product - Liposarcoma, Myxoid, Liposarcoma, Dedifferentiated | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 10 | 2022-02-02 | 2026-02-18 |
| A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas Eribulin, Pembrolizumab - Sarcoma, Liposarcoma | Phase 2 | Completed | Dana-Farber Cancer Institute | 57 | 2019-06-04 | 2025-08-28 |
| APX005M and Doxorubicin in Advanced Sarcoma Doxorubicin, APX005M - Soft Tissue Sarcoma | Phase 2 | Completed | Alexander Z. Wei, MD | 27 | 2019-03-20 | 2026-06-10 |
| Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma Eribulin, Lenvatinib - Leiomyosarcoma, Liposarcoma | Phase 1 / Phase 2 | Completed | National Taiwan University Hospital | 30 | 2018-07-12 | 2025-12-05 |
| Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab - Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 28 | 2017-12-14 | 2023-10-25 |
| Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine - Neoplasms | Phase 2 | Completed | GlaxoSmithKline | 23 | 2016-12-06 | 2023-04-11 |
| Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas MGCD516 - Liposarcoma, Metastatic Liposarcoma | Phase 2 | Completed | Columbia University | 29 | 2016-11-01 | 2024-07-18 |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Dexrazoxane, Doxorubicin - Sarcoma, Soft Tissue, Soft Tissue Sarcoma | Phase 2 | Completed | Washington University School of Medicine | 73 | 2016-02-22 | 2023-11-07 |
| Selinexor in Advanced Liposarcoma Selinexor, Placebo - Dedifferentiated Liposarcoma | Phase 2 / Phase 3 | Completed | Karyopharm Therapeutics Inc | 342 | 2016-01-04 | 2023-01-23 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 164 | 2015-08-13 | 2023-10-17 |
| Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas Pazopanib Hydrochloride, Oral Topotecan Hydrochloride, Laboratory Biomarker Analysis - Adult Liposarcoma, Metastatic Liposarcoma | Phase 2 | Completed | Northwestern University | 178 | 2015-03-21 | 2022-06-07 |
| Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery efatutazone - Liposarcoma | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 15 | 2015-02-11 | 2025-01-27 |
| Ph II Cabazitaxel DD Liposarcoma Cabazitaxel - Dedifferentiated Liposarcoma | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 42 | 2014-10-01 | 2021-09-14 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes Regorafenib, Placebo - Liposarcoma, Osteogenic Sarcoma | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 131 | 2014-07-01 | 2023-11-07 |
| Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma sirolimus and cyclophosphamide - Conventional Chondrosarcoma, Myxoid Liposarcoma | Phase 2 | Completed | Leiden University Medical Center | 70 | 2014-06-01 | 2022-04-20 |
| Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma Trabectedin - Liposarcoma, Leiomyosarcoma | Phase 2 | Completed | Italian Sarcoma Group | 105 | 2014-03-01 | 2021-11-01 |
| Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial Pazopanib - Advanced and / or Metastatic Liposarcoma | Phase 2 | Completed | Grupo Espanol de Investigacion en Sarcomas | 52 | 2013-01-29 | 2020-07-23 |
| Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Alisertib, Laboratory Biomarker Analysis - Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 72 | 2012-08-22 | 2017-11-30 |
Showing 20 of 47. Sign in to see all of them.
Sarcoma (32) · Leiomyosarcoma (26) · Fibrosarcoma (19) · Histiocytoma, Malignant Fibrous (19) · Sarcoma, Synovial (18) · Hemangiosarcoma (17) · Neurofibrosarcoma (16) · Rhabdomyosarcoma (15) · Hemangiopericytoma, Malignant (10) · Osteosarcoma (9) · Sarcoma, Alveolar Soft Part (9) · Malignant mesenchymal tumor (8) · Dermatofibrosarcoma (7) · Sarcoma, Endometrial Stromal (7)
Neoplasms by Histologic Type (47) · Neoplasms, Adipose Tissue (47) · Neoplasms, Connective and Soft Tissue (47) · Neoplasms (45) · Neoplasms, Connective Tissue (30) · Neoplasms, Muscle Tissue (28) · Neoplasms, Fibrous Tissue (25) · Histiocytoma (20) · Neoplasms, Nerve Tissue (19) · Neoplasms, Vascular Tissue (17) · Myosarcoma (16) · Nervous System Diseases (16) · Nervous System Neoplasms (16) · Neurofibroma (16) · Neuromuscular Diseases (16)
Doxorubicin (5) · Trabectedin (5) · pazopanib (5) · Cyclophosphamide (3) · Imatinib Mesylate (3) · Radiotherapy (3) · Dexamethasone (2) · Ifosfamide (2) · Sirolimus (2) · Sunitinib (2) · eribulin (2) · pembrolizumab (2) · temsirolimus (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · BI 2536 (1)
National Cancer Institute (NCI) (10) · European Organisation for Research and Treatment of Cancer - EORTC (6) · Dana-Farber Cancer Institute (3) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · Memorial Sloan Kettering Cancer Center (2) · Alexander Z. Wei, MD (1) · Alliance for Clinical Trials in Oncology (1) · Boehringer Ingelheim (1) · Columbia University (1) · Daiichi Sankyo (1) · GlaxoSmithKline (1) · Grupo Espanol de Investigacion en Sarcomas (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Italian Sarcoma Group (1) · Karyopharm Therapeutics Inc (1)
United States (31) · Belgium (8) · France (8) · Canada (7) · Germany (7) · United Kingdom (6) · Italy (5) · Spain (5) · Netherlands (4) · Denmark (3) · Australia (2) · Puerto Rico (2) · Sweden (2) · Taiwan (2) · China (1)
George D. Demetri, MD (3) · Robert Maki, MD, PhD (2) · Aaron R Weiss (1) · Alberto Chiappori, M.D. (1) · Alexander Wei, MD (1) · Annabel B.M. Foot (1) · Axel Le Cesne, MD (1) · Benjamin Izar, MD (1) · Bernd Kasper, MD (1) · Brian A Van Tine, M.D., Ph.D. (1) · Brian L Samuels, MD (1) · Christophe Bergeron (1) · Christopher W Ryan (1) · Claudia Valverde, MD (1)
PMID 31401903, PMID 19451433, PMID 32827353, PMID 10097144, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 17095209, PMID 17109446, PMID 17336054, PMID 19088049, PMID 19451429, PMID 20338746, PMID 20471824, PMID 20932656, PMID 21642514, PMID 22067397, PMID 23382028, PMID 23569312, PMID 27124835, PMID 27502708, PMID 29370992, PMID 30410720, PMID 31013172, PMID 32269142, PMID 32641862, PMID 32701199, PMID 32702309, PMID 34515544, PMID 35394800, PMID 36129471, PMID 36987836, PMID 37523624, PMID 38236580, PMID 39343511, PMID 39836945
P30CA006516 (2), P30CA008748 (2), U10CA098543 (2), U10CA180821 (2), 2004 (1), 2015 (1), N01CM62203 (1), N01CM62206 (1), P30CA012197 (1), P30CA015704 (1), P30CA060553 (1), R21CA117128 (1), U01CA069856 (1), U01CA154967 (1), U10CA031946 (1)